SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-04-1273. This Article Full Text (PDF) All Versions of this Article: 2002-04-1273v1 101/3/977    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Milazzo, C. Articles by Brossart, P. Search for Related Content PubMed PubMed Citation Articles by Milazzo, C. Articles by Brossart, P. Social Bookmarking                   What's this? Submitted April 30, 2002 Accepted August 27, 2002 Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA Caterina Milazzo, Volker L Reichardt*, Martin R Mueller, Frank Grunebach, and Peter Brossart Department of Hematology, Oncology, Immunology and Rheumatology, Tuebingen University Medical Center, Tuebingen, Germany * Corresponding author; email: volker.reichardt{at}med.uni-tuebingen.de. Current immunotherapeutical trials for patients with multiple myeloma (MM) focus on the idiotype (Id) as a tumor specific antigen for active immunization. To bypass the need for the identification of shared MM associated antigens and the characterization of possible immunogenic T-cell epitopes in a HLA type restricted manner, we focused on myeloma RNA transfection of dendritic cells (DC). Total RNA encodes the whole antigen content of tumor cells, therefore allowing the transfected DC to process and present the most relevant peptides and to induce a possible polyclonal CTL response against different immunogenic antigens. We transfected monocyte derived DC with total RNA from the myeloma cell lines LP-1 and U266 by electroporation and investigated the potential of these DC to induce myeloma specific CTL. We show that RNA transfected DC induce CTL that lyse the LP-1 and U266 myeloma cells in a antigen specific and MHC class I restricted manner, as demonstrated by cold target inhibition and antibody blocking studies. Interestingly, LP-1 specific CTL showed no specificity for the idiotype. Consistent with studies demonstrating MUC1 as a myeloma associated antigen we found MUC1 specificity of the CTL induced with U266 derived RNA. As corresponding epitopes we tested the described peptides M1.1 and M1.2 and found a striking fine specificity for M1.2, assuming a possible immunodominance of this peptide. This is the first report on the induction of myeloma specific CTL by RNA transfection of DC. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Martin-Ayuso, J. Almeida, M. Perez-Andres, R. Cuello, J. Galende, M. I. Gonzalez-Fraile, G. Martin-Nunez, F. Ortega, M. J. Rodriguez, J. F. San Miguel, et al. Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired Oncologist, January 1, 2008; 13(1): 82 - 92. [Abstract] [Full Text] [PDF] C. N. Boss, F. Grunebach, K. Brauer, M. Hantschel, V. Mirakaj, T. Weinschenk, S. Stevanovic, H.-G. Rammensee, and P. Brossart Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen Clin. Cancer Res., June 1, 2007; 13(11): 3347 - 3355. [Abstract] [Full Text] [PDF] F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia Cancer Res., June 1, 2006; 66(11): 5892 - 5900. [Abstract] [Full Text] [PDF] A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF] C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al. Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL J. Immunol., July 15, 2005; 175(2): 1301 - 1309. [Abstract] [Full Text] [PDF] S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384. [Abstract] [Full Text] [PDF] D. Dorfel, S. Appel, F. Grunebach, M. M. Weck, M. R. Muller, A. Heine, and P. Brossart Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA Blood, April 15, 2005; 105(8): 3199 - 3205. [Abstract] [Full Text] [PDF] C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy Blood, March 15, 2004; 103(6): 2046 - 2054. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020